Needham reiterates DocGo stock rating on SteadyMD strength By Investing.com

DocGo reported Q1 2026 revenue of $75.6M, topping consensus of $72.43M, but EPS came in at a $0.15 loss versus a $0.12 loss expected. Needham kept a Buy rating and $3.00 target, citing stronger-than-expected SteadyMD performance and a raised fiscal 2026 revenue outlook, while reaffirming profitability guidance despite higher SG&A. The stock remains around $0.59, down about 13% over the past week, indicating investors are still focused on execution risk.

Analysis

The market’s read-through is less about the headline AI drawdown and more about duration risk re-pricing: when policy/tax uncertainty hits a high-multiple semiconductor cohort, the first-order selloff can overstate fundamental damage but still compress near-term leadership. That matters because NVDA remains the marginal liquidity magnet for the AI trade; even a modest de-rating there can force de-grossing across data center suppliers, analog, and memory names as systematic funds reduce factor exposure rather than discriminate on fundamentals.

For DCGO, the interesting part is not the quarter’s noise but the setup for a second-half inflection if management really is seeing SG&A roll off sequentially. That creates a classic low-price, high-operating-leverage optionality profile: a small improvement in contribution margin can swing consensus EPS sharply because the market is still anchoring on losses. The risk is that execution slippage on cost takeout or a delayed ramp in SteadyMD extends the “promise” window by another 1-2 quarters, which would keep the stock trapped despite top-line progress.

Contrarian angle: the selloff may be overdone in the sense that policy headlines can hit semis faster than they hit earnings estimates, and the actual earnings damage may lag by a quarter or two. But that doesn’t mean dip-buying all AI beta works mechanically; the cleaner expression is to own the relative winners with less policy sensitivity and hedge the crowded high-duration basket. In healthcare microcaps like DCGO, the better trade is not to chase the absolute move but to wait for confirmation that cost cuts are visible in reported margins before paying for the turnaround.

Key Decisions for Investors

• Reduce outright NVDA beta for 1-2 weeks and re-enter only on stabilization in policy headlines; use the pullback to rotate into less factor-sensitive AI infrastructure names rather than the highest-multiple semi leader.
• Pair trade: long DCGO / short a higher-quality healthcare services name with less operating leverage over 1-3 months; the thesis is that small SG&A improvement can drive disproportionate upside if the second-half guide holds.
• For DCGO, consider a call spread 3-6 months out instead of stock if you want upside exposure to the margin inflection; this caps downside if execution slips while preserving convexity if EBITDA inflects.
• Use any additional weakness in NVDA to buy via staggered entries only after a 3-5 day base forms; the immediate risk/reward favors waiting for forced selling to clear rather than catching a falling factor basket.